American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma ...

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...

China's commitment to foster innovation and advance high-standard opening-up has provided global pharmaceutical companies ...

Hyderabad: As global trade wars rage on, sending countries and companies scrambling to de-risk their global supply chains, ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

Our Bureau, Mumbai Thursday, March 20, 2025, 09:00 Hrs [IST] CPHI & PMEC China, Asia's premier pharmaceutical event for sour ...

The largest of the collaborations is a potentially more than $4.68 billion partnership with Shanghai-based Harbour BioMed to discover and develop next-generation multi-specific antibodies for ...

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...